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ABSTRACT
This study presents data from a prospective study of adult patients with community-acquired
pneumonia (CAP). Of 493 patients included in the study, 223 (45.2%) were aged ‡ 65 years, and 265
(53.7%) had one or more underlying diseases, mostly chronic obstructive pulmonary disease, diabetes
mellitus or dementia. In total, 281 microorganisms were identiﬁed in 250 (50.7%) patients, with two or
more pathogens detected in 28 (5.7%) cases. Microbial diagnosis varied according to age, severity,
co-morbidity and site-of-care, but there was much overlap among groups. Streptococcus pneumoniae was
the single most prevalent organism in outpatients, patients admitted to hospital, and patients who died,
either as a single pathogen or combined with another organism. Infections caused by ‘atypical’
pathogens were seen across all groups, including the elderly and patients with co-morbidities. Mortality
varied according to the pneumonia severity index (PSI) of the pneumonia patient outcomes research
team. Shock (OR 34.48), an age of > 65 years (OR 25) and altered mental status (OR 9.92) were factors
associated independently with 30-day mortality. Key ﬁndings from this study were the advanced age of
the population with CAP, and the high prevalence of dementia as an underlying disease. The study also
revealed that microbiological diagnosis of CAP remains problematic. Although certain epidemiological
features may help to predict the microbial aetiology, the overlap among groups reduces the usefulness
of this information in guiding therapeutic decisions. Greater effort should be made to improve
identiﬁcation methods for microbial pathogens causing CAP.
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INTRODUCTION
Community-acquired pneumonia (CAP) is an
acute medical condition that is common world-
wide. It remains a major cause of admission to
hospital andmortality in developed countries, and
contributes signiﬁcantly to excessive consumption
of healthcare resources and related costs [1–4].
Pneumonia has always been an active ﬁeld of
investigation, given its relevance and complexity.
In the past decade, signiﬁcant progress has been
made in understanding the aetiology and out-
comes of patients with CAP. Chlamydia pneumoniae
has emerged as a signiﬁcant independent and
co-infecting pathogen [5,6], and epidemiological
research has provided prognostic and clinical-
decision support tools [7], as well as critical
pathways to optimise the healthcare process [8].
In addition, the beneﬁts resulting from immuni-
sation of speciﬁc patient groups with pneumococ-
cal polysaccharide have led to recommendations
for the use of this vaccine in patients at risk for
CAP [9].
In recent years, there have been further signiﬁ-
cant changes with respect to many aspects of CAP.
The selection of empirical therapy has become
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complicated by increasing concern regarding the
concurrent presence of ‘atypical’ pathogens (e.g.,
Mycoplasma pneumoniae, Chlamydia spp., Coxiella
burnetii and Legionella pneumophila) in a signiﬁcant
proportion of cases thought previously to be
caused by a single pathogen [5,10–18], and by the
marked rise of b-lactam and macrolide resistance
among Streptococcus pneumoniae isolates. While
most studies suggest that current levels of b-lactam
resistance do not usually result in treatment fail-
ures among patients with pneumococcal pneu-
monia [19,20], therapeutic failures attributable to
macrolide-resistant S. pneumoniae have been repor-
ted among patients treated with an oral macrolide
who required admission subsequently with S.
pneumoniae bacteraemia [21,22]. However, the
availability of newer ﬂuoroquinoloneswith greater
activity against S. pneumoniae and other respiratory
pathogens, as well as novel immunochromato-
graphic assays to detect S. pneumoniae and L.
pneumophila antigens in urine, have facilitated the
medical management of CAP [23–25].
Large-scale studies of the epidemiology of CAP
are labour-intensive, but the above-mentioned
changes and controversies mean that new epide-
miological data are required. Most previous
studies of CAP have focused either on patients
admitted to hospital or on outpatients [6,26–31].
The aim of the present work was to provide a
comprehensive overview of the current clinical
and epidemiological features of CAP by conduct-
ing a prospective population-based study with
two major advantages: (1) the inclusion of con-
secutive patients covering a broad clinical spec-
trum of CAP; and (2) an extensive microbiological
workup, including detection of urinary antigen
for S. pneumoniae and L. pneumophila, and stand-
ard serological tests and criteria for atypical and
virus pathogens. A previous report evaluated the
Binax immunochromatographic assay for detec-
tion of S. pneumoniae urinary antigen in the same
patient cohort [32]. The present study presents a
complete analysis of the epidemiological features,
microbial diagnosis and outcome for these
patients.
PATIENTS AND METHODS
Setting and population studied
This was a prospective observational cohort study conducted
between 15 October 1999 and 14 October 2001 at Hospital
General Universitario de Elche, a 430-bed university-afﬁliated
teaching hospital serving a population of 239 335 in three
municipalities of the Health Authority of Bajo Vinalopo´ on the
Mediterranean coast of Spain. All adult patients (‡ 15 years)
from this Health Authority with signs and symptoms com-
patible with pneumonia over the 24-month study period were
eligible for inclusion in the study. The study was approved by
the local Ethical Committee. Attending clinicians were asked
to consider the possibility of pneumonia in any patient with an
acute illness and symptoms suggesting lower respiratory tract
infection, including a new cough with high fever or chills,
pleuritic chest pain, dyspnoea or prolonged fever. Patients
were evaluated clinically and roentgenographically, and those
with a provisional diagnosis of CAP were seen by a study
investigator to conﬁrm the diagnosis. CAP was deﬁned as an
acute illness associated with at least one of the following signs
or symptoms: fever, new cough with or without sputum
production, pleuritic chest pain, dyspnoea or altered breath
sound on auscultation, plus a chest radiograph showing an
opacity compatible with the presence of acute pneumonia.
Patients who had been hospitalised previously within 2 weeks
of a current diagnosis of pneumonia were excluded.
Demographic and clinical data were collected by a study
investigator using a written standardised questionnaire. The
pneumonia severity index (PSI) of the pneumonia patient
outcomes research team (PORT) [7], which classiﬁes patients
into ﬁve risk classes according to outcome (stage I includes
patients with the most favourable prognosis, and stage V
includes those with the poorest prognosis), was used to
calculate the severity of pneumonia at presentation. A repeat
chest radiogram and a blood sample were obtained between 2
and 4 weeks after the initial diagnosis of CAP. Patients were
followed for at least 4 weeks or until death. Mortality was
deﬁned as death by any cause within 30 days of the diagnosis
of pneumonia.
Microbiological investigations
Laboratory investigations for a patient with CAP included
sputum samples for Gram’s stain and culture (only for patients
with productive cough), two blood samples for culture (only
for patients with fever ‡ 38C), urine sample for detection of
S. pneumoniae and L. pneumophila urinary antigens (all patients,
except those from whom a urine sample could not be collected
before starting antibiotic therapy), and serum samples for
serological testing, drawn during the acute and convalescent
phases of illness (all patients, except those who died before the
convalescent sample was due to be obtained or failed to attend
the follow-up visit). Any bronchoscopic samples obtained
were also cultured.
Only qualiﬁed sputum samples with > 25 white blood cells
and < 10 squamous cells ⁄ low-magniﬁcation ﬁeld (· 10) were
evaluated. Hospital staff in charge of patients were asked to
collect sputum samples before the start of antibiotic therapy.
The Binax immunochromatographic assays (Binax, Portland,
ME, USA) were used to detect S. pneumoniae antigen and
L. pneumophila serogroup I antigen in urine samples collected
at the time of diagnosis of CAP.
A complement ﬁxation (CF) test was performed to detect
antibodies againstM. pneumoniae, Chlamydia spp., Cox. burnetii,
inﬂuenza viruses A and B, respiratory syncytial virus and
adenovirus. CF tests followed a standard micromethod in
which heat-inactivated sera were titrated at a dilution of 1:64.
Four units of commercially available antigens (Institute Virion,
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Ru¨schlikon ⁄Zurich, Switzerland) and 4 U of guinea-pig com-
plement were used. The CF test antibody titre was read as the
highest dilution showing 50% haemolysis. An indirect immu-
noﬂuorescence test was used to detect antibodies against
L. pneumophila (Vircell, Granada, Spain), and a microimmuno-
ﬂuorescence test was used to detect antibodies against
C. pneumoniae, Chlamydia psittaci and Chlamydia trachomatis
(Vircell, Granada, Spain).
Criteria for aetiological diagnosis
The following criteria were used to classify a pneumonia as
being of known aetiology: (1) a four-fold or greater rise in
antibody titre by CF test for M. pneumoniae, C. psittaci, Cox.
burnetii, inﬂuenza viruses A and B, respiratory syncytial
virus and adenovirus; (2) a four-fold rise in antibody titres
to ‡ 1:128, or the presence of IgM antibodies (‡ 1:20) for C.
pneumoniae; (3) isolation from respiratory samples, or the
detection of antigen in urine, or a four-fold or greater rise in
immunoﬂuorescence antibody titre for L. pneumophila; (4)
isolation from blood or from pleural ﬂuid, or the predom-
inant organism isolated from a qualiﬁed sputum sample, or
antigen for S. pneumoniae detected in urine; (5) isolation from
blood or from pleural ﬂuid, or the predominant organism
isolated from a qualiﬁed sputum sample for Haemophilus
inﬂuenzae, Moraxella catarrhalis, Staphylococcus aureus and
other bacteria, including Gram-negative enterobacteria. Cases
that did not fulﬁl these diagnostic criteria were considered
to be ‘pneumonia of unknown aetiology’. Cases that fulﬁlled
the diagnostic criteria for more than one pathogen were
considered to represent ‘mixed pneumonia’. Cases with a
four-fold antibody rise against more than one species of
Chlamydia were excluded from the deﬁnition of mixed
pneumonia because of possible non-speciﬁc cross-reactions.
Statistical analysis
Descriptive statistics were computed by standard methods.
Differences between speciﬁed groups were detected by the chi-
square test, or Fisher’s exact test where appropriate, for
categorical variables, and the Mann–Whitney U-test or Stu-
dent’s t-test for continuous variables. Multivariable analysis of
factors potentially associated with mortality was performed by
stepwise logistic regression, including all signiﬁcant variables
in univariate analysis and all clinically important variables,
whether signiﬁcant or not. A two-tailed p value of 0.05 was
considered signiﬁcant. Associations between independent
variables and outcomes were assessed by the odds ratio (OR)
and its 95% conﬁdence interval (CI). Statistical analyses were
performed with SPSS v. 11 software (SPSS Inc., Chicago, IL,
USA).
RESULTS
Patient characteristics
Of 516 patients with signs and symptoms com-
patible with pneumonia, 23 were found sub-
sequently not to have CAP (8 · lower respiratory
tract infection without pneumonia; 7 · heart fail-
ure; 2 · pulmonary embolism; 2 · lung cancer;
1 · bronchiectasis; 1 · atelectasis; 1 · pulmonary
ﬁbrosis; 1 · pulmonary haemorrhage), leaving
493 patients in the study cohort. The main
demographic characteristics of these patients are
summarised in Table 1. In total, 361 (73.2%)
patients were admitted to hospital for a mean
(SD) stay of 6.45 (6.46) days. The remaining 132
(26.8%) patients were managed as outpatients.
The mean (SD) PSI score in patients admitted to
hospital was 80.8 (35.3), compared to 36.3 (19.5) in
outpatients (p < 0.001). All ambulatory patients
were classiﬁed within risk classes I and II of the
PSI. The distribution of patients admitted to
hospital according to PSI risk classes was as
follows: I ⁄ II 144 (39.9%), III 97 (26.9%), IV 92
(25.5%), and V 28 (7.8%).
Some patient characteristics varied according to
age. Co-morbid illnesses were more common in
patients aged ‡ 65 years than in younger patients
(73.5% vs. 23.5%; p < 0.001). Predisposing factors
for aspiration pneumonia (reduced level of con-
sciousness, underlying neurological disease, dys-
phagia, impaired gag reﬂex, or severe periodontal
disease) were also signiﬁcantly more frequent in
patients aged ‡ 65 years than in younger patients
(22.9% vs. 3.3%; p < 0.001).
Table 1. Characteristics of 493 patients with community-
acquired pneumonia
Characteristic No. (%) patients
Age, mean (range), 56.6 years (15–94 years)
Distribution of cases by age group
15–44 years 161 (32.7)
45–64 years 109 (22.1)
65–74 years 87 (17.6)
‡ 75 years 136 (27.6)
Male gender 308 (62.5)
Regular cigarette use 111 (22.5)
Heavy alcohol consumption 63 (12.8)
Intravenous drug use 3 (0.6)
Predisposing cause for aspirationa 60 (12.2)
Underlying disease 227 (46)
Chronic obstructive pulmonary disease 99 (20.1)
Diabetes mellitus 98 (19.9)
Dementia 52 (10.5)
Immunosuppression 26 (5.3)
Neoplasia 21 (4.3)
Congestive heart failure 20 (4.1)
Chronic renal failure 17 (3.4)
Previous antibiotic therapyb 114 (23.1%)
Distribution according to PSI score
I ⁄ II 267 (54.2)
III 103 (20.9)
IV 94 (19.1)
V 29 (5.9)
Admission to hospital 361 (73.2)
PSI, pneumonia PORT (patient outcome research team) severity index.
aReduced level of consciousness, underlying neurological disease, dysphagia,
impaired gag reﬂex, severe periodontal disease.
bA wide variety of agents, including b-lactams, macrolides, tetracyclines and
quinolones.
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Results of microbiological investigations and
aetiological agents identiﬁed
Specimens obtained included blood cultures from
302 (61.2%) patients, urine from 454 (92.1%),
acute and follow-up serum from 401 (81.3%),
sputum from 272 (55.2%), and lower respiratory
secretions obtained by a bronchoscopic procedure
from 14 (2.8%). In total, 280 pathogens (140
bacteria, 110 atypical pathogens and 30 viruses)
were identiﬁed in 250 (50.7%) patients (Table 2).
A single pathogen was detected in 222 (45%)
patients and two or more pathogens in 28 (5.7%)
patients. The most frequent aetiological agents
were S. pneumoniae (16.8%), M. pneumoniae
(7.7%), Chlamydia spp. (6.3%), L. pneumophila
(4.1%), Gram-negative bacilli, including Pseudo-
monas spp. (3.2%), and inﬂuenza virus (2.8%).
In 243 (49.3%) cases, the microbial aetiology
remained unknown. A wide variety of combina-
tions of pathogens was found among patients
with CAP of mixed aetiology, with the most
frequent combinations being a bacterial pathogen
plus an atypical organism (eight cases) and two
bacterial pathogens (eight cases). The most com-
mon mixed infections were S. pneumoniae with
L. pneumophila (three cases), S. pneumoniae
with Pseudomonas spp. (three cases), S. pneumoniae
withM. pneumoniae (two cases), S. pneumoniaewith
inﬂuenza virus (two cases), M. pneumoniae with
inﬂuenza virus (two cases), and C. pneumoniae
with L. pneumophila (two cases).
Microbial aetiology by age and co-morbidity
The distribution of the causative microorganisms
by age group is shown in Table 3. S. pneumoniae
was the single most prevalent organism in all
groups, except in the youngest patients, where
Mycoplasma was identiﬁed more frequently. Over-
all, bacterial pathogens accounted for 26.5% (59 of
223 cases) of pneumonias in patients aged
‡ 65 years, compared with 19.3% (52 of 270 cases)
in younger patients (p 0.06). Pneumonias caused
by Gram-negative bacilli, including Pseudomonas
spp., were also more common in older patients; 12
(75%) of the 16 cases were diagnosed in patients
aged ‡ 65 years. Atypical pathogens were more
prevalent in younger patients, and showed a
declining trend with age. There were no signi-
ﬁcant trends according to age group in the
incidence of pneumonia caused by other
pathogens.
Co-morbidity was also related to the aetiology
of CAP (Table 4). Overall, infections caused by
atypical pathogens were seen more frequently in
patients without co-morbidities, whereas bacterial
infections tended to occur more commonly in
patients with underlying conditions. S. pneumoni-
ae was the single most prevalent organism in both
groups, but was detected more frequently in
patients with underlying disease (21.1% vs.
13.3%; p 0.02). Pneumonias caused by Gram-
negative enteric bacilli or Pseudomonas spp. were
also more common among patients with co-mor-
bid conditions, where they accounted for 5.3% of
the cases, compared with 1.5% in patients with-
out co-morbid conditions (p 0.02). Overall, of 111
episodes of bacterial infection, 65 (58.6%)
occurred in patients with co-morbidities, com-
pared with 45 (40.5%) in patients without under-
lying disease (p 0.002). In contrast to bacterial
infections, 66 (72.5%) of 91 episodes of atypical
infection occurred in patients without underlying
disease, compared with 25 (27.5%) in patients
with co-morbidities (p < 0.001). In patients
Table 2. Results of microbiological investigations per-
formed on specimens obtained from 493 patients with
community-acquired pneumonia
Microbiological investigation
No. (%) patients with positive
result/total no. of patients for
whom the test was performed
Serological testing (acute and
convalescent samples)
122 ⁄ 401 (30.4)
Mycoplasma pneumoniae 45
Chlamydia spp.a 34
Legionella pneumophila 27
Inﬂuenza virus 22
Respiratory syncytial virus 5
Coxiella burnetii 4
Varicella-zoster virus 2
Adenovirus 1
Urinary antigen detection 119 ⁄ 454 (26.2)
Streptococcus pneumoniae 104
Legionella pneumophila 15
Gram’s stain and culture from respiratory
specimens (sputum + bronchoscopic samples)
52 ⁄ 286b (18.2)
Streptococcus pneumoniae 15
Pseudomonas spp. 14
Haemophilus inﬂuenzae 11
Gram-negative bacilli
other than Pseudomonas spp.c
6
Staphylococcus aureus 4
Moraxella catarrhalis 2
Blood cultures 17 ⁄ 302 (5.6)
Streptococcus pneumoniae 13
Pseudomonas spp. 2
Escherichia coli 1
Listeria monocytogenes 1
aChlamydia pneumoniae (18 cases), Chlamydia psittaci (10 cases). In six cases, there was
a four-fold rise in antibodies against both Chlamydia psittaci and Chlamydia
pneumoniae.
bOf the 286 specimens, 272 were expectorated sputum and 14 were bronchoscopic
samples.
cKlebsiella spp. (three cases), Enterobacter spp. (one case), Citrobacter spp. (one case),
Stenotrophomonas spp. (one case).
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without co-morbidity, atypical organisms were
the most frequent group of pathogens, accounting
for 25% of all pneumonia cases. Interestingly,
whereas pneumonias caused by Mycoplasma and
Chlamydia spp. were more common among
patients without co-morbidity, the prevalence of
Table 3. Distribution of the causative microorganisms identiﬁed in 493 patients with community-acquired pneumonia
according to age group
Microorganism
Total (n = 493)
No. (%)
Aged 15–44 years
(n = 161) No. (%)
Aged 45–64 years
(n = 109) No. (%)
Aged 65–74 years
(n = 87) No. (%)
Aged ‡ 75 years
(n = 136) No. (%)
Bacterial pathogens 111 (22.5) 29 (18.0) 23 (21.1) 23 (26.4) 36 (26.5)
Streptococcus pneumoniae 83 (16.8) 23 (14.3) 17 (15.6) 17 (19.5) 26 (19.1)
Pseudomonas spp. 11 (2.2) 2 (1.2) 2 (1.8) 2 (2.3) 5 (3.7)
Haemophilus inﬂuenzae 9 (1.8) 2 (1.2) 4 (3.7) 2 (2.3) 1 (0.7)
Gram-negative bacilli other
than Pseudomonas spp.a
5 (1.0) 0 0 1 (1.1) 4 (2.9)
Staphylococcus aureus 2 (0.4) 2 (1.2) 0 0 0
Moraxella catarrhalis 1 (0.2) 0 0 1 (1.1) 0
Atypical pathogens 91 (18.5) 44 (27.3)b 25 (22.9) 12 (13.8) 10 (7.4)
Mycoplasma pneumoniae 38 (7.7) 28 (17.4)c 3 (2.8) 4 (4.6) 3 (2.2)
Legionella pneumophila 21 (4.3) 4 (2.5) 10 (9.2) 5 (5.7) 2 (1.5)d
Chlamydia spp.e 30 (6.1) 10 (6.2) 12 (11.0) 3 (3.4) 5 (3.7)
Coxiella burnetii 2 (0.4) 2 (1.2)
Virus pathogens 20 (4.1) 5 (3.1) 5 (4.6) 5 (5.7) 5 (3.7)
Inﬂuenza virus 14 (2.8) 3 (1.9) 5 (4.6) 3 (3.4) 3 (2.2)
Respiratory syncytial virus 4 (0.8) 0 0 2 (2.3) 2 (1.5)
Adenovirus 1 (0.2) 1 (0.6) 0 0 0
Varicella-zoster virus 1 (0.2) 1 (0.6) 0 0 0
Mixed aetiologyf 28 (5.7) 10 (6.2) 6 (5.5) 3 (3.4) 9 (6.6)
Unknown 243 (49.3) 73 (45.3) 50 (45.9) 44 (50.6) 76 (55.9)
aKlebsiella spp. (two cases), Escherichia coli (one case), Citrobacter spp. (one case), Stenotrophomonas spp. (one case).
bp 0.001 for the comparison with the rest of the patients.
cp < 0.001 for the comparison with the rest of the patients.
dp 0.007 for the comparison with the rest of the patients.
eChlamydia pneumoniae (15 cases), Chlamydia psittaci (nine cases). In six cases, there was a four-fold rise in antibodies against both C. psittaci and C. pneumoniae.
fS. pneumoniae and L. pneumophila (three cases), S. pneumoniae and Pseudomonas spp. (three cases), S. pneumoniae and M. pneumoniae (two cases), S. pneumoniae and inﬂuenza
virus (two cases), M. pneumoniae and inﬂuenza virus (two cases), L. pneumophila and C. pneumoniae (two cases), S. pneumoniae and Haemophilus spp. (one case), S. pneumoniae
and S. aureus (one case), S. pneumoniae and Klebsiella spp. (one case), S. pneumoniae and Enterobacter spp. (one case), S. pneumoniae and Moraxella catarrhalis (one case),
S. pneumoniae and Coxiella burnetii (one case), M. pneumoniae and H. inﬂuenzae (one case), C. psittaci and Listeria monocytogenes (one case), C. pneumoniae and Cox. burnetti (one
case), L. pneumophila and inﬂuenza virus (one case), inﬂuenza virus and varicella-zoster virus (one case), inﬂuenza virus and respiratory syncytial virus (one case),
S. pneumoniae, M. pneumoniae and inﬂuenza virus (one case), M. pneumoniae, S. pneumoniae and Staphylococcus aureus (one case).
Table 4. Distribution of the causative microorganisms identiﬁed in 493 patients with community-acquired pneumonia
according to co-morbidity
Microorganism
Absence of co-morbiditya
(n = 264) No. (%)
Underlying conditionsa
(n = 227) No. (%)
COPD (n = 99)
No. (%)
Diabetes mellitus
(n = 98) No. (%)
Dementia
(n = 52) No. (%)
Bacterial pathogens 45 (17.0) 65 (28.6) 29 (29.3) 26 (26.5) 14 (26.9)
Streptococcus pneumoniae 35 (13.3) 48 (21.1) 18 (18.2) 22 (22.4) 11 (21.2)
Pseudomonas spp. 3 (1.1) 8 (3.5) 6 (6.0)b 2 (2.0) 1
Haemophilus inﬂuenzae 5 (1.9) 4 (1.8) 2 1 0
Gram-negative bacilli other
than Pseudomonas spp.c
1 (0.4) 4 (1.8) 2 1 2
Staphylococcus aureusd 1 (0.4) 0 0 0 0
Moraxella catarrhalis 0 1 (0.4) 1 0 0
Atypical pathogens 66 (25.0)e 25 (11.0) 10 (10.1) 18 (18.4) 4 (7.7)
Mycoplasma pneumoniae 30 (11.4)e 8 (3.5) 2 6 2
Legionella pneumophila 11 (4.2) 10 (4.4) 6 5 1
Chlamydia spp.f 23 (8.7)g 7 (3.1) 2 6 1
Coxiella burnetii 2 (0.8) 0 0 0 0
Virus pathogens 10 (3.9) 10 (4.4) 2 (2.0) 6 (6.1) 4 (7.7)
Inﬂuenza virus 8 (3.0) 6 (2.6) 1 4 3
Respiratory syncytial virus 0 4 (1.8) 1 2 1
Adenovirus 1 (0.4) 0 0 0 0
Varicella-zoster virus 1 (0.4) 0 0 0 0
Mixed aetiology 9 (3.4) 18 (7.9) 7 (7.1) 1 (1.0) 7 (13.5)
Unknown 134 (50.8) 109 (48.0) 51 (51.5) 47 (48.0) 23 (44.2)
COPD, chronic obstructive pulmonary disease.
aOne or more of the following conditions: diabetes, chronic lung or heart disease, chronic liver disease, chronic renal insufﬁciency, cancer, immunosuppression, dementia,
malnutrition. Information about underlying conditions was unavailable for two patients.
bp 0.015 for the comparison with patients without underlying conditions.
cKlebsiella spp. (two cases), Escherichia coli (one case), Citrobacter spp. (one case), Stenotrophomonas spp. (one case).
dData regarding underlying disease were unavailable for one of the patients.
ep 0.001 for the comparison with patients with underlying conditions.
fChlamydia pneumoniae (15 cases), Chlamydia psittaci (nine cases). In six cases, there was a four-fold rise in antibodies against both C. psittaci and C. pneumoniae.
gp 0.01 for the comparison with patients with underlying conditions.
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L. pneumophila was the same in patients with or
without co-morbidities. The overall frequency of
virus infections was also similar in patients with
or without underlying disease, but all pneumo-
nias caused by respiratory syncytial virus were
seen in patients with co-morbidities.
The aetiological distribution found in patients
with the three major underlying diseases is shown
in Table 4. Of particular note is the leading
position of S. pneumoniae in all groups, and the
signiﬁcant association of Pseudomonas spp. with
chronic obstructive pulmonary disease.
Aetiology by severity and site-of-care
Microbial diagnosis of CAP also varied according
to severity and site-of-care, but S. pneumoniae was
the single most prevalent organism in all speciﬁed
groups. In patients classiﬁed into low-severity
risk classes (I–III) of the PSI, S. pneumoniae
(14.9%), M. pneumoniae (8.9%) and C. pneumoniae
(4.9%) were the pathogens detected most
frequently (Table 5). Compared to patients in
high-severity risk classes, those classiﬁed in low-
severity classes had a higher prevalence of atyp-
ical pathogens (20.8% in classes I–III vs. 11.4% in
classes IV ⁄V; p 0.02). The main aetiological agents
identiﬁed in the high-severity risk classes (IV ⁄V)
were S. pneumoniae (22.8%), L. pneumophila (4.1%)
and M. pneumoniae (4.1%). Chlamydia spp. were
very rare among patients in high-severity risk
classes (Table 5).
The distribution of aetiological agents by site-
of-care mimicked the distribution according to
severity (Table 6). S. pneumoniae was the organism
detected most frequently in both inpatients and
outpatients. The only signiﬁcant difference
between inpatients and outpatients was in the
prevalence of infections caused by atypical path-
ogens; these occurred more frequently in outpa-
tients than in patients admitted to hospital (27.3%
vs. 15.2%; p 0.004). Fifteen (93.7%) of the 16 cases
of pneumonia caused by Gram-negative bacilli or
Pseudomonas spp. were diagnosed in patients who
were admitted to hospital.
Outcomes and factors associated with mortality
Analysis of different variables showed a lower rate
of hospital admission for patients with atypical
aetiology (60.4%) compared with bacterial (79.1%;
p 0.005) and unknown (74.9%; p 0.01) aetiology.
The hospitalisation rate was highest for patients
infected with Gram-negative bacilli, including
Pseudomonas spp. (93.3%), followed by those infec-
ted with more than one organism (82.2%), pneu-
mococci (77.1%), unidentiﬁed organisms (74.9%),
viruses (70%) and M. pneumoniae (55.3%). Exclu-
ding patients who died, the mean (range) hospital
stay was 8.87 (1–52) days. The mean period of
hospitalisation was longer for patients with bac-
terial pneumonia (11.44 ± 8.95 days) than for those
with atypical pathogens (7.36 ± 4.21 days; p 0.001)
and viral pneumonia (7.64 ± 3.57 days; p 0.009).
Table 5. Distribution of the
causative microorganisms identiﬁed
in 493 patients with community-
acquired pneumonia according to
severity
Microorganism
Low-severity risk classes
(I–III) of the PSI (n = 370)
No. (%)
High-severity risk classes
(IV/V) of the PSI (n = 123)
No. (%) p
Bacterial pathogens 74 (20.0) 37 (30.1) 0.02
Streptococcus pneumoniae 55 (14.9) 28 (22.8) 0.05
Pseudomonas spp. 7 (1.9) 4 (3.3) NS
Haemophilus inﬂuenzae 7 (1.9) 2 (1.6) NS
Gram-negative bacilli other
than Pseudomonas spp.a
2 (0.5) 3 (2.4) NS
Staphylococcus aureus 2 (0.5) 0 NS
Moraxella catarrhalis 1 (0.3) 0 NS
Atypical pathogens 77 (20.8) 14 (11.4) 0.02
Mycoplasma pneumoniae 33 (8.9) 5 (4.1) 0.08
Legionella pneumophila 15 (4.1) 6 (4.9) NS
Chlamydia spp.b 27 (7.3) 3 (2.4) 0.05
Coxiella burnetii 2 (0.5) 0 NS
Virus pathogens 15 (4.1) 5 (4.1) NS
Inﬂuenza virus 11 (3.0) 3 (2.4) NS
Respiratory syncytial virus 2 (0.5) 2 (1.6) NS
Adenovirus 1 (0.3) 0 NS
Varicella-zoster virus 1 (0.3) 0 NS
Mixed pneumonia 17 (4.6) 11 (8.9) NS
Unknown 187 (50.5) 56 (45.5) NS
PSI, pneumonia patient outcomes research team (PORT) severity index; NS, not signiﬁcant.
aKlebsiella spp. (two cases), Escherichia coli (one case), Citrobacter spp. (one case), Stenotrophomonas spp. (one case).
bChlamydia pneumoniae (15 cases), Chlamydia psittaci (nine cases). In six cases, there was a four-fold rise in antibodies
against both C. psittaci and C. pneumoniae.
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Of 490 patients for whom treatment informa-
tion was available, 223 (45.5%) received com-
bined therapy with a macrolide plus a b-lactam
antibiotic, 106 (21.6%) received monotherapy
with a b-lactam, 46 (9.4%) received a macrolide
alone, 85 (17.3%) received a ‘respiratory’ ﬂuoro-
quinolone, and 30 (6.1%) received other antibio-
tics. The antibiotics prescribed varied according
to site-of-care. Monotherapy with macrolides was
prescribed predominantly in the outpatient set-
ting (30 (65.2%) of 46 prescriptions), whereas
combined therapy was given mostly to patients
admitted to hospital (191 (85.7%) of 223 prescrip-
tions). Forty-three (50.6%) of 85 courses of ﬂuor-
oquinolones were administered to outpatients,
and 42 (49.4%) to hospitalised patients.
Of 361 patients admitted to hospital, 24 died
within the 4-week follow-up period, with a
mortality rate of 6.6% (95% CI, 4.40–9.87). Caus-
ative pathogens identiﬁed in 11 (45.8%) of the 24
patients who died were S. pneumoniae (n = 6),
Pseudomonas spp. (n = 1), Escherichia coli (n = 1)
and mixed infections (S. pneumoniae with Pseudo-
monas spp. in two cases, and S. pneumoniae with
Staph. aureus in one case). Five (3.8%) of the 132
ambulatory patients eventually required hospital
admission, but all ﬁve had a favourable outcome.
The overall mortality rate, including both inpa-
tients and outpatients, was 4.8% (95% CI, 3.21–
7.26). Mortality according to the PSI risk classes
was as follows: (1) classes I ⁄ II, 0.75% (two of 266
cases); (2) class III, 1.96% (two of 102 cases);
(3) class IV, 11.82% (11 of 93 cases); and (4) class
V, 32.14% (nine of 28 cases). In addition to PSI
risk class, the following variables were associated
signiﬁcantly with mortality by univariate analy-
sis: age > 65 years, presence of co-morbidity,
shock, altered mental status at admission,
increased respiratory rate (> 30 ⁄min), respiratory
failure (PO2 ⁄FIO2 < 300), renal failure (creatinine
> 150 mmol ⁄L), bacteraemia, aspiration pneumo-
nia, and antibiotic therapy not including a
macrolide or a ﬂuoroquinolone (Table 7). No
association was found between gender, previous
antibiotic therapy, immunodepression, tempera-
ture at presentation, white blood cell count,
multilobar involvement, Gram-negative pneu-
monia or infection with Pseudomonas spp., and
mortality.
In the multivariate analysis, shock (OR 34.48),
age > 65 years (OR 25) and altered mental status
(OR 9.92) were the only independent predictors
of mortality that were statistically signiﬁcant.
The potential association between antimicrobial
regimens and either complications or mortality
was explored by univariate and multivariate
analysis in different subgroups of patients. There
was no association between combined antimicro-
bial therapy and either complications or mortality
in patients with any particular aetiology of CAP,
including bacterial pneumonia, mixed pneu-
monia, pneumococcal pneumonia, or Gram-neg-
ative pneumonia. Although an association was
found between combined antimicrobial therapy,
Table 6. Distribution of the
causative microorganisms identiﬁed
in 493 patients with community-
acquired pneumonia according to
site-of-care
Microorganism
Patients admitted to
hospital (n = 361)
No. (%)
Outpatients
(n = 132)
No. (%) p
Bacterial pathogens 88 (24.4) 23 (17.4) NS
Streptococcus pneumoniae 64 (17.7) 19 (14.4) NS
Pseudomonas spp. 10 (2.8) 1 NS
Haemophilus inﬂuenzae 6 (1.7) 3 (2.3) NS
Gram-negative bacilli other
than Pseudomonas spp.a
5 (1.4) 0 NS
Staphylococcus aureus 2 0 NS
Moraxella catarrhalis 1 0 NS
Atypical pathogens 55 (15.2) 36 (27.3) 0.004
Mycoplasma pneumoniae 21 (5.8) 17 (12.9) 0.009
Legionella pneumophila 17 (4.7) 4 (3.0) NS
Chlamydia spp.b 17 (4.7) 13 (9.8) 0.05
Coxiella burnetti 2 0 NS
Virus pathogens 14 (3.9) 6 (4.5) NS
Inﬂuenza virus 10 (2.8) 4 (3.0) NS
Respiratory syncytial virus 4 (1.1) 0 NS
Adenovirus 0 1 NS
Varicella-zoster virus 0 1 NS
Mixed aetiology 23 (6.4) 5 (3.8) NS
Unknown 175 (48.5) 62 (46.9) NS
NS, not signiﬁcant.
aKlebsiella spp. (two cases), Escherichia coli (one case), Citrobacter spp. (one case), Stenotrophomonas spp. (one case).
bChlamydia pneumoniae (15 cases), Chlamydia psittaci (nine cases). In six cases, there was a four-fold rise in antibodies
against both C. psittaci and C. pneumoniae.
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including either a macrolide or a ﬂuoroquinolone,
and reduced mortality by univariate analysis, the
association was not conﬁrmed by multivariate
analysis.
DISCUSSION
This prospective study provides comprehensive
data for a large cohort of patients with CAP and
offers updated epidemiological information that
may be especially relevant in light of recent
developments in many aspects of this disease.
The uniform sampling in all groups of patients,
the comprehensive search for microorganisms,
and the use of standard diagnostic tests and
criteria to establish the aetiological diagnosis form
an important addition to our present knowledge
of the epidemiology of CAP.
Among the most interesting observations from
the cohort were the older age of the population,
compared with previous population-based stud-
ies [33–39], and the high prevalence of dementia
as an underlying disease. The older age of the
population may have accounted in part for the
higher proportion of patients admitted to hospital
compared with other population-based studies
carried out in the last decade. In the present
study, dementia emerged as a signiﬁcant co-mor-
bid illness in patients with CAP, ranking after
chronic obstructive pulmonary disease and dia-
betes mellitus. Pneumonia is one of the most
serious medical conditions seen in late-stage
dementia, and is a common cause of death in
these patients [40]. The high prevalence of
dementia observed in the present study is prob-
ably related to population ageing, which was also
reﬂected in the older age of the patients included
in the study. Although Alzheimer’s disease is an
increasing problem in the elderly, affecting
4.5 million individuals in the USA alone [41],
the presence of dementia was not found to be a
major risk factor for CAP in epidemiological
studies published in the last decade. However, a
recent study of CAP in patients aged ‡ 80 years
admitted to hospital found that dementia was the
fourth most common underlying disease after
chronic obstructive pulmonary disease, chronic
heart disease and diabetes mellitus [42]. Patients
with dementia may be particularly susceptible to
pneumonia because of their swallowing difﬁcul-
ties and the use of sedative medications, which
are factors that have been found to increase the
risk of pneumonia in elderly patients living in
long-term care facilities [43,44]. The problem of
pneumonia in patients with dementia may be
more serious in the future in view of forecasts of a
continued increase in the number of individuals
with Alzheimer’s disease [41].
A disappointing ﬁnding of the study was the
fact that, despite the introduction of urinary
antigen testing for S. pneumoniae and L. pneumo-
phila, and the extensive serological tests per-
formed, the aetiology remained unidentiﬁed for
half of the cases, conﬁrming that microbial diag-
nosis of CAP remains problematic. However,
neither non-serological tests for viruses (e.g.,
immunoﬂuorescence, virus culture) nor nucleic
acid ampliﬁcation techniques were used, and no
attempt was made to look for emerging viruses,
such as coronavirus, human metapneumovirus or
hantavirus. The results obtained showed a high
proportion of patients with pneumococcal CAP.
S. pneumoniae was the most frequent organism
identiﬁed, both in outpatients and in patients
requiring admission to hospital, and it was also
the most frequent pathogen involved in mixed
infections and in fatal cases. This ﬁnding con-
curs with the results of previous studies of
Table 7. Variables associated with
mortality in 493 patients with
community-acquired pneumonia by
univariate analysis
Characteristic
Survived (n = 469)
No. (%)
Died (n = 24)
No. (%) OR 95% CI p
Age > 65 years 194 ⁄ 469 (41.4) 22 ⁄ 24 (91.7) 15.62 3.62–66.66 < 0.001
Predeﬁned underlying conditionsa 203 ⁄ 467 (43.5) 24 ⁄ 24 (100%) 1.12 1.07–1.17 < 0.001
Shock 5 ⁄ 465 (1.1) 6 ⁄ 24 (25) 30.30 8.55–111.11 < 0.001
Altered mental status at admission 36 ⁄ 432 (7.7) 16 ⁄ 24 (66.7) 24.0 9.62–59.88 < 0.001
Increased respiratory rate (> 30 ⁄min) 38 ⁄ 468 (8.1) 9 ⁄ 24 (37.5) 6.80 2.79–16.67 < 0.001
Respiratory failure (PO2 ⁄ FIO2 < 300) 172 ⁄ 381 (45.1) 18 ⁄ 21 (85.7) 7.30 2.11–25 < 0.001
Renal failure (creatinine > 150 mmol ⁄L) 33 ⁄ 465 (7.1) 6 ⁄ 23 (26.1) 4.59 1.69–12.35 0.007
Bacteraemia 13 ⁄ 465 (2.8) 3 ⁄ 24 (12.5) 4.98 1.31–18.87 0.03
Aspiration pneumonia 15 ⁄ 455 (3.3) 12 ⁄ 24 (50) 29.41 11.36–76.92 < 0.01
Antibiotic therapy not including
a macrolide or a ﬂuoroquinolone
124 ⁄ 466 (26.6) 12 ⁄ 24 (50) 2.75 1.21–6.29 0.01
Data are no. patients ⁄no. for whom data were available (%), unless otherwise indicated.
aOne or more of the following conditions: diabetes, chronic lung or heart disease, chronic liver disease, chronic
renal insufﬁciency, cancer, immunosuppression, dementia, malnutrition.
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hospitalised patients [8], but the frequency of
S. pneumoniae in outpatients has varied widely
[6,27–29,35,38,45]. Some studies have identiﬁed
atypical organisms, such as M. pneumoniae [6,28]
and C. pneumoniae [35], or viruses [46], more
frequently than S. pneumoniae, but these differ-
ences probably reﬂect the different populations
studied and the types of diagnostic test per-
formed.
The results of the present study support the
high prevalences of CAP caused by atypical
pathogens reported previously [5,6,29,30,47],
reaching 36% of all diagnosed cases in the present
cohort, with M. pneumoniae accounting for 41.8%
of all atypical pathogens. This observation agrees
with the results of other studies in whichM. pneu-
moniae has accounted for up to 60% of all atypical
pathogens [5,29,47], reinforcing the pivotal role of
this organism in CAP. In contrast, the importance
of C. pneumoniae is not yet completely understood.
In the last few years, C. pneumoniae has been
identiﬁed with increasing frequency in some
studies, reaching a proportion comparable to
and ever higher than that of Mycoplasma [34,47],
but has been found rarely in other cohorts [28,29].
The lack of a reference standard for diagnosis,
combined with the occurrence of epidemic out-
breaks during some studies, may account in part
for the wide variations in the reported incidence
rates. In order to determine the signiﬁcance of C.
pneumoniae as a cause of pneumonia in a popu-
lation, it is critical to use standard diagnostic tests
and criteria, and to perform studies for a sufﬁ-
cient length of time to avoid any seasonal bias.
The present study used CDC criteria [48] for
diagnosing deﬁnite acute infection by serology,
and patients were recruited over a 2-year period.
According to the results, C. pneumoniae is a
signiﬁcant pathogen in CAP, but its frequency is
lower than that ofM. pneumoniae, and much lower
than that found in other pneumonia studies
[6,34,47].
On comparison of aetiology by age group and
co-morbidity, there were many similarities, but
also some differences. Overall, the prevalence of
CAP caused by atypical organisms was highest
among young adults and patients without
co-morbidities, reﬂecting the epidemiological pat-
tern of Mycoplasma and Chlamydia infections. In
contrast, pneumonias caused by Legionella were
seen with similar frequency in young and
older individuals, and in patients with or without
co-morbidities. Although Mycoplasma and Chla-
mydia infections were more common in the
youngest patients, 22% of all cases of pneumonia
caused by these organisms occurred in patients
aged > 65 years. These ﬁndings agree with other
studies reporting signiﬁcant incidence rates of
CAP caused by atypical pathogens in the elderly
[49] and in patients with co-morbidities [50]. With
regard to the aetiological distribution according to
underlying diseases, S. pneumoniae held the lead-
ing position in all groups, while there was a
signiﬁcant association between Pseudomonas spp.
and chronic obstructive pulmonary disease. Cases
of staphylococcal pneumonia among diabetic
patients were not observed.
On analysis of aetiology by site-of-care and
severity, S. pneumoniae was again the single most
prevalent organism both in patients admitted to
hospital and in outpatients, and in low- and high-
severity risk classes, emphasising that empirical
antibiotic therapy should always be active against
pneumococci. The incidence of CAP caused by
atypical pathogens, including M. pneumoniae and
C. pneumoniae, was highest among outpatients,
but was also high among hospitalised patients.
The importance of M. pneumoniae, C. pneumoniae
and Legionella in pneumonias requiring hospital-
isation has been highlighted in several previous
studies of CAP [30,51,52]. Although atypical
pathogens other than Legionella spp. have usually
been associated with mild-to-moderate illness,
severe cases requiring admission to an intensive
care unit have also been reported [53]. In the
CBPIS study [30], pneumonia caused by M. pneu-
moniae and C. pneumoniae accounted for between
8% (using criteria for deﬁnite diagnosis) and 35%
(using criteria for possible diagnosis) of all
patients with pneumonia who required hospital-
isation. A recent study found that CAP patients
aged ‡ 60 years with Chlamydia infection had the
highest hospitalisation rate, leading to the sug-
gestion that pneumonia caused by Chlamydia can
rival even pneumococcal pneumonia for severity
[47]. However, little information was actually
available on the severity at presentation of atyp-
ical pneumonia using a validated prognostic tool.
The results of the present study, using the
validated PORT prediction rule for 30-day mor-
tality and medical complications to quantify
severity of illness at presentation, suggest that
the severity of CAP caused by atypical organisms
may have been overestimated. Indeed, most
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patients with CAP caused by M. pneumoniae or C.
pneumoniae had a disease of low severity, and all
such patients had a favourable outcome. Accord-
ing to current recommendations [2], most of these
cases should probably have been treated at home.
Legionella spp. have long been considered to be
some of the most common pathogens causing
severe CAP. However, the frequency with which
Legionella spp. have been identiﬁed in case series
of severe CAP has ranged from 21.8% [54] to 5%
[55], and these organisms were found only rarely
in large French studies [56,57]. Recent population-
based data show that most cases of Legionella
infection probably present as mild-to-moderate
disease, rather than severe pneumonia [58,59]. In
the largest outbreak of Legionnaires’ disease to
date, with more than 800 cases reported, one-third
of the patients were managed as outpatients and a
case fatality rate of only 1.1% was observed [58].
In the present population-based study using the
PORT classiﬁcation, of 21 cases of Legionnaires’
disease, 15 (71.4%) were classiﬁed within ‘low-
severity’ and six (28.6%) within ‘high-severity’
risk classes. Four (19%) of the 21 cases were
managed as outpatients, only one (6%) of the 17
patients admitted required treatment in the inten-
sive care unit, and none of these patients died.
The importance of epidemiological data in
guiding empirical therapeutic decisions for
patients with CAP has been recognised in differ-
ent guidelines from specialist scientiﬁc societies
[1–3]. Thus, patients with CAP are often classiﬁed
into groups, each with a list of likely pathogens
and a suggested empirical therapy, based on
stratiﬁcation according to age, place of therapy,
co-morbidity and severity [1–3]. The present data
conﬁrmed that microbial diagnosis varies accord-
ing to epidemiological factors, but there was too
much overlap between groups for this informa-
tion to be used as a guide for therapeutic
decisions. Selection of empirical therapy is com-
plicated further by the marked increase in
b-lactam and macrolide resistance among isolates
of S. pneumoniae, and by the increasing concern
about mixed infections [5,10–14]. A low propor-
tion of cases of CAP in the present study were
considered to be of mixed aetiology. Mixed
infections were seen across all age groups, inclu-
ding elderly patients, and in both hospitalised
patients and outpatients [29,30,34].
Although the importance of treating multiple
infecting pathogens has not been established,
several observational studies indicate that the
use of a macrolide with a cephalosporin, as part of
an initial empirical regimen for patients with CAP
admitted to hospital, may be associated with a
shorter length of hospital stay and a lower
mortality rate than treatment with a cephalospo-
rin alone [60–63]. In addition, recent data suggest
an advantage in using an empirical b-lactam–
macrolide combination, rather than monotherapy,
for the treatment of CAP that is associated
subsequently with pneumococcal bacteraemia
[16,17,64]. However, all of these investigations
were retrospective, with design limitations and
several sources of bias [65]. In the present study,
combined therapy was not associated with a
better outcome in the multivariate analysis when
compared with monotherapy. Although the fre-
quent involvement of pneumococci in mixed
pneumonias would support a role for dual ther-
apy in pneumococal infection, no association was
demonstrated between combined antibiotic ther-
apy and outcome in patients with pneumococcal
pneumonia. Although these ﬁndings may argue
against the use of dual therapy in patients with
pneumococcal pneumonia, the results should be
interpreted with caution because the relatively
small size of the groups affects the power and
general applicability of the ﬁndings. In addition,
as stated in the updated guidelines for CAP from
the Infectious Diseases Society of America [2],
until such time as a prospective, randomised trial
clariﬁes this issue, identiﬁcation of pneumococci
should not prevent clinicians from pursuing
other diagnostic possibilities (e.g., an ‘atypical’
co-pathogen), especially when the pneumonia is
not responding to treatment.
The overall mortality rate in the present study
was 4.8%, which is a ﬁgure similar to that found in
other recent community-based studies of CAP
[34,35,47]. For patients requiring hospitalisation,
the 6.6%mortality rate resembles the rate of 8.8%
in the CBPIS study [30], but is lower than other
ﬁgures reported previously, which have averaged
12% [3]. Age, disease severity and underlying
disease, as reﬂectedby thePSI prediction rule,were
factors that affected outcome. Indeed, mortality
varied according to the PSI, with most fatal cases
occurring in patients classiﬁed within risk classes
IV and V. Although several variables were associ-
ated with mortality in the univariate analysis, only
shock, an age > 65 years and an altered mental
status were associated independently with
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increased mortality. As stated above, no associ-
ation was found in multivariate analysis between
mortality and either monotherapy or combination
antibiotic therapy.
In summary, this study of CAP, conducted at
the beginning of the 21st century, has conﬁrmed
many epidemiological features known from pre-
vious studies, but has also disclosed interesting
and novel aspects of this disease. The study
conﬁrmed that microbial diagnosis of CAP
remains problematic, and that the aetiology still
cannot be identiﬁed in a considerable proportion
of cases. Although certain epidemiological fea-
tures may help to predict the microbial aetiology,
the overlap between groups reduces the useful-
ness of this information in guiding therapeutic
decisions. New microbiological techniques are
required to improve the ability of laboratories to
detect microbial pathogens causing CAP.
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